We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+10.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$176M
AUM Growth
+$4.87M
Cap. Flow
-$868K
Cap. Flow %
-0.49%
Top 10 Hldgs %
54.6%
Holding
85
New
17
Increased
11
Reduced
21
Closed
12

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$3.05M
2
CMPS
Compass Pathways
CMPS
+$2.52M
3
ENGN icon
enGene Therapeutics
ENGN
+$2.23M
4
RLMD icon
Relmada Therapeutics
RLMD
+$1.94M
5
CLDX icon
Celldex Therapeutics
CLDX
+$1.91M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$3.6M
2
KLAC icon
KLA
KLAC
+$2.93M
3
CSTL icon
Castle Biosciences
CSTL
+$2.22M
4
IMNM icon
Immunome
IMNM
+$1.78M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Technology 21.04%
3 Energy 4.89%
4 Materials 0.6%
5 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ILMN icon
76
Illumina
ILMN
$28.2B
– –
-6,000
Closed -$787K
INBX icon
77
Inhibrx
INBX
$1.28B
– –
-3,698
Closed -$292K
LQDA icon
78
Liquidia Corp
LQDA
$7.11B
– –
-10,000
Closed -$345K
MASI
79
DELISTED
Masimo
MASI
– –
-8,280
Closed -$1.08M
RAPT
80
DELISTED
RAPT Therapeutics
RAPT
– –
-15,000
Closed -$508K
TMCI icon
81
Treace Medical Concepts
TMCI
$279M
– –
-226,947
Closed -$556K
TXG icon
82
10x Genomics
TXG
$5.55B
– –
-59,000
Closed -$962K
VTYX
83
DELISTED
Ventyx Biosciences
VTYX
– –
-100,827
Closed -$910K
ALMS
84
Alumis Inc
ALMS
$3.65B
– –
-10,000
Closed -$97.6K
BHVN
85
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-59,365
Closed -$670K
1 2 3
4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Birchview Capital held 85 positions worth $176M, up 2.8% from $171M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Birchview Capital's Q1 2026 filing shows 17 new, 11 increased, 21 reduced and 12 closed positions. Its largest new stake was Ocular Therapeutix: 320,000 shares worth $2.71M. The largest sale was Amicus Therapeutics, an estimated $3.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 76% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q1 2026 buy was Ocular Therapeutix: 320,000 shares worth $2.71M.
  • Birchview Capital added most to Pacific Biosciences in Q1 2026, an estimated $1.79M increase.
  • Birchview Capital's biggest Q1 2026 reduction was KLA, cutting an estimated $2.93M.
  • Birchview Capital fully exited Amicus Therapeutics in Q1 2026, selling an estimated $3.6M.
  • Birchview Capital's ten largest holdings make up 55% of its $176M portfolio in Q1 2026.
  • Birchview Capital opened 17 new positions and closed 12 in Q1 2026.
  • Birchview Capital's portfolio value rose 2.8% quarter-over-quarter to $176M.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.